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Abstract
Background: Thiazide diuretics are commonly prescribed to prevent kidney stones. However, it is unclear whether higher 
doses confer greater benefit.
Objective: To determine whether lower doses of thiazide diuretics confer a similar protective effect against kidney stone 
events as higher doses.
Design: Population-based cohort study.
Setting: Linked health administrative databases in Ontario, Canada.
Patients: Older adults newly prescribed a thiazide diuretic between 2003 and 2014 were separated into 2 groups based on 
daily dose: low dose (⩽12.5 mg hydrochlorothiazide/chlorthalidone, or ⩽1.25 mg indapamide) or high dose.
Measurements: The primary outcome was time to a kidney stone event, using diagnosis and procedure codes. A secondary 
outcome was kidney stone surgery.
Methods: An association between thiazide diuretic dose and a kidney stone event was estimated using Cox proportional 
hazards regression.
Results: A total of 536 of 105 239 patients (0.51%) experienced a kidney stone event. We did not detect a difference in 
kidney stone risk in the high-dose relative to the low-dose group (adjusted hazard ratio, 1.10; 95% confidence interval, 0.93-
1.31). Results were similar when analysis was restricted to the more specific outcome of kidney stone surgery. Neither a 
history of prior kidney stones nor the type of thiazide diuretic modified the effect of diuretic dose on outcome.
Limitations: Patients were >65 years old and we were unable to adjust for some potential confounders such as dietary 
factors.
Conclusions: Lower dose thiazide diuretics appear to confer a similar protective effect as higher dose thiazides against the 
development of kidney stones.
Abrégé 
Contexte: Les diurétiques thiazidiques sont couramment prescrits pour prévenir la formation de calculs rénaux. On ignore 
toutefois si l’administration de doses plus élevées confère de plus grands avantages.
Objectif de l’étude: Déterminer si de faibles doses de diurétiques thiazidiques confèrent un effet protecteur contre la 
formation de calculs rénaux similaire à celui des doses plus élevées.
Type d’étude: Une étude de cohorte représentative de la population.
Cadre: Les bases de données administratives interreliées du système de santé de la province de l’Ontario au Canada.
Patients: L’étude porte sur des patients âgés auxquels un diurétique thiazidique avait été nouvellement prescrit entre 2003 
et 2014. Les sujets ont été séparés en deux groupes, selon la dose quotidienne prescrite : un premier groupe traité à faible 
dose d’hydrochlorothiazide ou de chlorthalidone (12,5 mg ou moins) ou d’indapamide (1,25 mg ou moins) et un deuxième 
groupe traité à des doses plus élevées.
Mesures: Le principal critère d’intérêt était le laps de temps écoulé avant la survenue de calculs rénaux, établi d’après les 
codes de procédures et de diagnostic. Le critère secondaire consistait en une intervention chirurgicale visant l’extraction de 
calculs rénaux.
Méthodologie: L’association entre la dose de diurétique thiazidique et la survenue de calculs rénaux a été estimée par la 
méthode de régression à risques proportionnels de Cox.
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Résultats: Des 105 239 patients retenus pour l’étude, 536 (0,51 %) ont vécu un épisode de calculs rénaux. Aucun écart 
significatif dans le risque de développer des calculs rénaux n’a pu être décelé entre les deux groupes et donc, selon la 
dose prescrite (rapport de risque ajusté : 1,10; I.C. à 95 % : 0,93 – 1,31). Des résultats similaires ont été obtenus lorsque 
l’analyse se limitait spécifiquement aux interventions visant l’extraction de calculs rénaux. De plus, il a été observé que ni les 
antécédents de calculs rénaux ni le type de diurétique thiazidique prescrit n’avaient modulé l’effet de la dose sur le résultat.
Limites de l’étude: Les patients retenus pour l’étude étaient âgés de 65 ans et plus, et nous n’avons pas été en mesure de 
tenir compte de potentielles variables confusionnelles telles que les habitudes alimentaires.
Conclusion: L’administration d’une faible dose de diurétique thiazidique semble conférer un effet protecteur contre la 
formation de calculs rénaux similaire à celui offert par une dose plus élevée.
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What was known before
Prior studies found that higher dose thiazide diuretics lower 
urinary calcium excretion to a greater degree than lower dose 
thiazides. Whether or not this translates into a difference in 
clinical outcomes is not clear as there are no data examining 
the relative ability of higher vs lower dose thiazide diuretics 
to prevent kidney stones.
What this adds
Using a large population-based administrative data set from 
people greater than 65 years of age we find that lower dose 
thiazide diuretics (⩽12.5 mg hydrochlorothiazide/chlorthali-
done or ⩽1.25 mg indapamide) have a similar ability to pre-
vent kidney stone formation as higher dose thiazides.
Introduction
Kidney stones are common and associate with significant 
morbidity and high health care costs.1,2 Hypercalciuria is the 
most common metabolic risk factor for the development of 
kidney stones.3 Numerous studies (including several ran-
domized trials)4-6 have shown the efficacy of thiazide diuret-
ics for both lowering urinary calcium excretion and the 
subsequent likelihood of future kidney stone episodes.7-9 
High doses of thiazide diuretics were used in the trials (ie, 
⩾50 mg of hydrochlorothiazide or ⩾ 25 mg chlorthalidone 
daily), and such doses are associated with a greater frequency 
of side effects, including electrolyte disturbance, hypergly-
cemia, hyperlipidemia, and glucose intolerance.10 In clinical 
practice, lower doses are commonly employed for hyperten-
sion and also for the treatment of hypercalciuria.11-13 
However, whether lower doses of thiazides are equally as 
effective at preventing kidney stones is not known and a sig-
nificant knowledge gap identified in guidelines from the 
American College of Physicians.8
In this study, we determined whether initiating treatment 
with a low vs high dose of a thiazide diuretic is associated 
with an altered risk of kidney stones. We hypothesized that 
low doses of thiazide diuretics are as effective at preventing 
kidney stones as higher doses.
Methods
This study employed the thiazide diuretic users from a previ-
ously generated cohort.9 In that study, we described in detail 
the population data sources, cohort entry criteria, baseline 
covariates, and the identification of kidney stone events. In 
brief, we employed linked administrative health data to create 
a retrospective, population-based cohort of individuals older 
than 65 years of age (a segment of the Ontario population 
where drug coverage is a universal benefit), with a new pre-
scription for 1 of 4 classes of antihypertensives (angiotensin-
converting enzyme inhibitors/angiotensin receptor blockers 
[ACEi/ARB], beta blockers, calcium channel blockers, and 
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thiazide diuretics) between April 1, 2003, and March 31, 
2014. The date of prescription served as the index date. We 
excluded patients with missing age or sex data, patients with 
previous antihypertensive use in the 180 days prior to index 
date (to ensure new use) or evidence of use of other drugs that 
might alter kidney stone risk (ie, furosemide, prednisone, or 
topiramate), patients with end-stage renal disease, and those 
with a hospital admission in the previous 90 days prior to 
index date. For the current study, we restricted to thiazide 
diuretic users only (hydrochlorothiazide, chlorthalidone, or 
indapamide), excluding patients prescribed the thiazide 
diuretic metolazone due to its small sample size (n = 254). A 
list of thiazide diuretic drug identification numbers is pro-
vided in Supplemental Table 1. We further divided thiazide 
diuretic users into a low-dose and a high-dose group. 
Individuals prescribed a low-dose thiazide diuretic were used 
as the referent category for all analyses. Low-dose hydrochlo-
rothiazide was considered ⩽12.5 mg per day, low-dose 
chlorthalidone was considered ⩽12.5 mg per day, and low-
dose indapamide was considered ⩽1.25 mg per day. The 
index date for our study (date where we started follow-up) 
was set as the date that the thiazide diuretic was prescribed. 
All doses higher than those detailed above were considered 
high dose.
We obtained vital statistics from the Registered Persons 
Database (RPDB). The Ontario Drug Benefit (ODB) data-
base was used to acquire prescription drug data.14 The 
Canadian Institute for Health Information Discharge Abstract 
Database (CIHI-DAD) was employed to identify baseline 
comorbidity data, hospital admissions, and kidney stone epi-
sodes. Emergency room visits were captured with the CIHI 
National Ambulatory Care Reporting System (NACRS) 
database. Physician billing claims from the Ontario Health 
Insurance Plan (OHIP) as well as diagnosis and procedural 
codes from the CIHI-NACRS and CIHI-DAD databases 
were employed to identify kidney stone episodes. Other rel-
evant episodes requiring an interaction with the health care 
system and some baseline comorbidities were captured in the 
OHIP database. The data sets were linked using unique, 
encoded identifiers derived from health card numbers, and 
patient-level data were analyzed at the Institute for Clinical 
Evaluative Sciences (ICES). The reporting of this and our 
prior study followed the guidelines for observational studies 
(Supplemental Table 2).9,15
Baseline covariates included age and sex, obtained from 
the RPDB and socioeconomic status, which was determined 
based on neighborhood income quintile according to 
Statistics Canada.9 Records in the 5 years prior to the index 
date were used to identify baseline comorbidities including 
alcoholism, chronic liver disease, dementia, diabetes, heart 
failure, history of kidney stones, human immunodeficiency 
virus, hypercalcemia, hyperparathyroidism, hypertension, 
inflammatory bowel disease, leukemia, peripheral vascular 
disease, and stroke/transient ischemic attack. Three years of 
hospitalization records prior to the index date were used to 
calculate the Charlson comorbidity index, which was calcu-
lated based on the adaptation by Quan et al.16 Baseline 
demographic, comorbidity, and treatment data were reported 
for each dose group according to the index thiazide diuretic 
prescribed.
The primary outcome was first presentation with kidney 
stones to a primary care physician, emergency department, 
or hospital following index dose of thiazide diuretic pre-
scribed. These outcomes were captured using OHIP, CIHI-
DAD, and NACRS databases, employing a validated 
algorithm17-19 based on International Classification of 
Diseases, Tenth Revision (ICD-10-CA) diagnostic codes. 
Supplemental Table 3 lists the diagnostic codes employed to 
identify the outcomes.
Statistical Analysis
Variables were complete with no missing values except for 
income quintile (0.3% missing) and rural residence (<0.1% 
missing). Standardized differences were used to assess the 
balance in baseline variables between groups, with a stan-
dardized difference of more than 10% being considered 
potentially important.20
Patients were followed from the time of the index thiazide 
diuretic prescription until the occurrence of the primary out-
come, death, a prescription for a different antihypertensive 
(ACEi/ARB, beta blocker, calcium channel blocker), no sub-
sequent refill prescription (stop), or the end of the study fol-
low-up period (March 31, 2015), whichever event came first. 
Given the lack of an effect of other antihypertensive pre-
scriptions on the risk of kidney stone presentation, we also 
repeated this analysis without censoring when another anti-
hypertensive medication was started. A continuous user of a 
thiazide diuretic was defined by evidence of a repeat pre-
scription within a period of time equivalent to 150% of the 
days supplied for the previous prescription.21 Individuals 
were censored 365 days after their last prescription meeting 
this definition, in order to permit a formed kidney stone to 
become clinically apparent. Less than 0.5% of patients emi-
grate from the province each year, and this was a minor rea-
son for not filling repeat prescriptions in the provincial drug 
database.
We used Cox proportional hazards regression with low-
dose thiazide diuretics as the referent group, to estimate the 
hazard ratio (HR) and 95% confidence interval (CI) of a kid-
ney stone event according to the dose of thiazide diuretic 
(low vs high) prescribed. Models were adjusted for the fol-
lowing factors, defined a priori: age (per 1 year), sex (male 
referent), number of primary care provider visits in the prior 
year (per 1 visit), location (urban referent), Charlson comor-
bidity score (per 1 unit increase), history of stroke, diabetes, 
hypertension, hypercalcemia, hyperparathyroidism, history 
of kidney stones, and inflammatory bowel disease. 
Supplemental Table 4 lists the specific codes used to identify 
these characteristics.
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Several sensitivity analyses were performed. First, the out-
come definition was restricted to a kidney stone requiring sur-
gical intervention. We examined kidney stone risk as per the 
primary analysis, but without censoring for starting another 
antihypertensive. We examined kidney stone risk as per the 
primary analysis after excluding individuals receiving 
chlorthalidone. We examined the risk separately for those 
patients who remained on the same dose, compared with those 
who switched dose group in the first 90 days. This analysis, 
similar to others, examined stone events from the time of ini-
tial prescription, not from the time of switching dose. We also 
adjusted for a prior stone history. Consequently, for this analy-
sis, experiencing a stone event should not influence dose 
adjustment. We used interaction terms to determine whether 
the presence or absence of a history of kidney stones in the 5 
years prior to the index date, or whether the type of thiazide 
prescribed on the index date, modified the association between 
thiazide diuretic dose and the risk of kidney stones. Finally, we 
used an extended Cox model to assess the effect of thiazide 
dose, low vs high, on kidney stone events, allowing recurrent 
events. Kidney stone events separated by at least 45 days were 
considered distinct events and included in the model.
All analyses were conducted with SAS version 9.4 (SAS 
Institute, Cary, North Carolina, 2011) according to a prespeci-
fied protocol approved by the institutional review board at 
Sunnybrook Health Sciences Centre (Toronto, Ontario, 
Canada). Participant informed consent was not required for this 
study. Two-sided P values <.05 were considered significant.
Results
Cohort Characteristics
We identified 105 239 persons older than the age of 65 years 
who started a new prescription for a thiazide diuretic. In our 
prior analysis, individuals prescribed a thiazide diuretic had a 
significantly reduced risk of having a kidney stone event rela-
tive to those prescribed another type of antihypertensive medi-
cation (adjusted hazard ratio [HR
adj
] = 0.77, 95% CI: 0.69-0.85, 
P < .01).9 We divided the patients receiving a thiazide diuretic 
into 2 groups based on total daily dose: low dose (⩽12.5 mg 
hydrochlorothiazide or chlorthalidone or ⩽1.25 mg indap-
amide; n = 49 942) and high dose (n = 55 297). Baseline char-
acteristics were similar between groups (Table 1; median age 
of 73 years, 0.8% with a kidney stone event in the last 5 years), 
although the high-dose group tended to be slightly younger 
and live in rural areas. The overall follow-up of the cohort was 
a median of 365 days (interquartile range [IQR], 248-571), 
which was not different between groups. The total follow-up 
of the cohort was 163 516 person-years.
Relationship Between Dose of Thiazide 
Prescribed and Kidney Stone Events
Of the 49 942 patients on a low-dose thiazide diuretic, 244 
(0.49%) had a kidney stone event (2.95 events per 1000 
person-years). This was very similar in the high-dose group, 
with 292 events (0.53%) from 55 297 persons receiving a 
new prescription (3.62 events per 1000 person-years). In 
unadjusted analyses, a high vs low dose of thiazide diuretic 
was associated with a higher risk of a kidney stone event 
(HR
unadj
 = 1.19, 95% CI: 1.01-1.41), which was attenuated 
after adjustment (HR
adj
 = 1.10, 95% CI: 0.93-1.31) (Table 2). 
Using the more specific outcome of stone-related surgery 
produced similar results (HR
adj
 = 1.18, 95% CI: 0.96-1.46) 
(Table 2).
Our previous work failed to detect an effect of other anti-
hypertensives on the risk of developing a kidney stone.9 We 
therefore repeated these analyses without censoring when 
another antihypertensive medication was prescribed (Table 
2). This longer follow-up period (median = 439 days, IQR = 
365-1040) increased the proportion of individuals experienc-
ing a kidney stone event in both groups to 378 (0.76%) in the 
low-dose group and to 424 (0.77%) in the high-dose group. 
This analysis also did not detect an altered risk in the high-
dose group relative to the low-dose group (HR
adj
 = 1.03, 95% 
CI: 0.89-1.18, P = .70), including when examining for the 
more specific outcome of kidney stone surgery (HR
adj
 = 1.08, 
95% CI: 0.91-1.28, P = .36). These data are consistent with 
lower dose thiazide diuretics conferring a similar effect to 
high-dose thiazide diuretics on the rate of presenting with a 
kidney stone event.
Sensitivity Analyses
To evaluate the potential effect of switching from a low- to a 
high-dose thiazide diuretic thereby biasing our results, we 
examined the risk of having a kidney stone in those that 
remained on either low or high dose and in those that 
switched to a different dose group within 90 days of initial 
prescription (Table 3). This analysis demonstrated an 
increased risk in the small number of patients (n = 1693), 
who started the study on a high dose then switched to a low-
dose relative to those who remained on the low-dose through-
out (HR
adj
 = 2.19, 95% CI: 1.28-3.78, P = .005). Interestingly, 
those who remained on the high dose did not have an 
increased risk of presenting with a kidney stone (HR
adj
 = 
1.11, 95% CI: 0.92-1.33), nor did the patients whose dose 
escalated from low to high dose (HR
adj
 = 1.19, 95% CI: 0.86-
1.64) relative to those who continued a low-dose thiazide 
diuretic.
To avoid the potentially confounding effect of different 
thiazide diuretics, we repeated the analysis after excluding 
patients receiving chlorthalidone. This did not alter the pri-
mary outcome. Persons on a higher dose thiazide diuretic 
had a similar risk of kidney stones (HR
adj
 = 1.12, 95% CI: 
0.94-1.33, p = 0.21). We also examined whether our primary 
analysis was modified by history of prior kidney stone and 
did not find an effect modification (Table 4, P = .42). Persons 
with a history of a kidney stone in the prior 5 years had simi-
lar risk of recurrence (HR
adj
 = 1.26, 95% CI: 0.74-2.13). We 
also assessed whether thiazide diuretic type modified our 
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Table 1. Baseline Characteristics.
Characteristics
Low dose (referent) High dose
Standardized 
differencean % n %
Total patients 49°942 47.4 55°297 52.5 —
Demographics
 Age at cohort entry
 Mean ± SD 74.55 ± 6.88 73.76 ± 6.77 12%
 Median (IQR) 73 (69-79) 72 (68-78) —
  66-70 years 17°818 35.7 22°676 41.0 11%
  71-75 years 12°433 24.9 13°394 24.2 2%
  76-80 years 9514 19.1 9538 17.2 5%
  81-85 years 6214 12.4 5933 10.7 5%
  ⩾86 years 3963 7.9 3756 6.8 4%
 Socioeconomic status
  1 (poorest) 9133 18.3 10°536 19.1 2%
  2 10°061 20.1 11°474 20.7 1%
  3 9548 19.1 10°628 19.2 0%
  4 9982 20.0 11°005 19.9 0%
  5 (richest) 11°076 22.2 11°461 20.7 4%
  Missing 142 0.3 193 0.3 0%
 Sex
  Female 34°699 69.5 36°809 66.6 6%
  Male 15°243 30.5 18°488 33.4 6%
 Locationb
  Urban 42°847 85.8 45°329 82.0 10%
  Rural 7077 14.2 9944 18.0 10%
  Missing 18 0.0 24 0.0 1%
 Year of cohort entry
  2003 5475 11.0 6085 11.0 0%
  2004 7795 15.6 8703 15.7 0%
  2005 6632 13.3 6924 12.5 2%
  2006 5292 10.6 5529 10.0 2%
  2007 4441 8.9 4915 8.9 0%
  2008 4038 8.1 4257 7.7 1%
  2009 3550 7.1 3991 7.2 0%
  2010 3368 6.7 3802 6.9 1%
  2011 3092 6.2 3581 6.5 1%
  2012 2980 6.0 3618 6.5 2%
  2013 2679 5.4 3166 5.7 1%
  2014 600 1.2 726 1.3 1%
Health care access in the past 1 year
 Primary care physician visits
  Mean ± SD 6.49 ± 6.7 6.53 ± 7.51 1%
  Median (IQR) 5 (3-8) 5 (2-8) —
  0 visits 3016 6.0 4216 7.6 6%
  1-2 visits 8832 17.7 10°627 19.2 4%
  ⩾3 visits 38°094 76.3 40454 73.2 7%
 Urologist consults 3738 7.5 4214 7.6 0%
Comorbidities in the past 5 years
 Alcoholism 128 0.3 230 0.4 2%
 Chronic liver disease 1214 2.4 1330 2.4 0%
 Dementia 3027 6.1 3388 6.1 0%
 Diabetesc 1283 2.6 1853 3.4 5%
 Heart failure 1249 2.5 1710 3.1 4%
 History of kidney stoned 376 0.8 449 0.8 0%
 (continued)
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Characteristics
Low dose (referent) High dose
Standardized 
differencean % n %
 HIV 34 0.1 33 0.1 0%
 Hypercalcemia 32 0.1 27 0.0 4%
 Hyperparathyroidism 22 0.0 27 0.0 4%
 Hypertension 33°790 67.7 36°867 66.7 2%
 Inflammatory bowel disease 221 0.4 216 0.4 0%
 Leukemia 497 1.0 522 0.9 1%
 Peripheral vascular disease 198 0.4 251 0.5 1%
 Stroke/TIA 436 0.9 574 1.0 1%
 Charlson comorbidity indexe
  Mean ± SD 0.11 ± 0.56 0.12 ± 0.59 2%
  Median (IQR) 0 (0-0) 0 (0-0) —
  0 47°305 94.7 52°055 94.1 3%
  1 1177 2.4 1496 2.7 2%
  2 961 1.9 1125 2.0 1%
  ⩾3 499 0.9 621 1.3 4%
 Number of unique drugs prescribedf
  Mean ± SD 2.92 ± 3.02 2.93 ± 3.19 0%
  Median (IQR) 2 (1-4) 2 (1-4) —
  <6 drugs 41°861 83.8 45°883 83.0 2%
  6-10 drugs 6701 13.4 7611 13.8 1%
  11-15 drugs 1145 2.3 1493 2.7 3%
  16-20 drugs 194 0.4 246 0.4 0%
  21-25 drugs 33 0.1 48 0.1 0%
  ⩾26 drugs 8 0.0 16 0.0 0%
Note. IQR = interquartile range; TIA = transient ischemic attack; DIN = drug identification number.
aStandardized differences are less sensitive to sample size than traditional hypothesis tests. They provide a measure of the difference between groups 
divided by the pooled standard deviation; a value greater than 10% is interpreted as a meaningful difference between the groups.20
bRural residence was defined as a population <10 000 people.
cDiabetes was considered to be use of any medication used to treat diabetes in the last 180 days preceding the index date (Supplemental Table 4).
dDocumented kidney stone event in the preceding 5 years.
eCharlson comorbidity index12 was calculated using 3 years of hospitalization data. “No hospitalizations” received a score of 0.
fBaseline medication use in the 1 year preceding the index date.
Table 1. (continued)
results. For patients treated with either hydrochlorothiazide 
or indapamide, the risk of developing a kidney stone event 
by dose of drug was unaltered by specific thiazide type. 
Finally, we examined the effect of thiazide dose on the risk of 
kidney stones, allowing multiple events per individual (Table 
5). This increased the total number of events to 654. High-
dose thiazide, relative to low-dose thiazide, was not associ-
ated with kidney stones, even when allowing multiple kidney 
stone events (HR
adj
 = 1.11, 95% CI: 0.95-1.30).
Discussion
In a large population of persons receiving a new prescription 
for a thiazide diuretic, we found that lower dose thiazide 
diuretics confers a statistically similar protective effect com-
pared with higher dose diuretics. Our results were robust to 
the more specific definition of requiring kidney stone sur-
gery and were not modified by having a history of prior 
kidney stones. This work provides support for using lower 
dose thiazide diuretics to prevent recurrent kidney stone 
episodes.
Our inability to find an effect of thiazide dose on kidney 
stone risk could be explained by the fact that thiazide diuret-
ics reduce kidney stone risk independently of their urinary 
calcium lowering effect or that thiazides have a similar abil-
ity to reduce calciuria at a range of doses. However, the lim-
ited evidence available supports that higher doses of 
hydrochlorothiazide have a greater urinary calcium lowering 
effect.13,22 The nature of our cohort is such that we do not 
have information about urinary calcium excretion or the 
influence of thiazide dose on calciuria. However, in several 
trials examining the protective effect of thiazide diuretics, a 
protective effect was demonstrated even though hypercalci-
uria was not an inclusion criterion.5,23,24 Consistent with this, 
we did not find an effect modification by history of kidney 
stones in our current or prior analysis (albeit the confidence 
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intervals were wide), consistent with thiazide diuretics being 
protective regardless of the presence of this metabolic 
abnormality.9
The median follow-up of our cohort was 365 days. This is 
a relatively short time as it may take considerably longer for 
a kidney stone to form and become clinically apparent. 
Nonetheless, in a prior study employing this cohort we dem-
onstrated a clear reduction in the risk of forming a kidney 
stone when an individual was prescribed a thiazide diuretic 
in comparison to another antihypertensive.9 This is consis-
tent with the possibility that thiazide diuretics might have 
another effect on kidney stone formation/presentation, such 
as stabilizing calculi in situ, lowering urinary oxalate excre-
tion or urinary pH, independent of lowering urinary calcium 
excretion.25,26
A recent meta-analysis by Fink et al clearly highlights the 
utility of thiazide diuretics in preventing further kidney stone 
events in persons with a history of kidney stones.8 The trials 
included in this review were completed in the 1980s and early 
1990s when much higher doses of thiazide diuretics were uti-
lized than are currently employed in clinical practice for the 
treatment of hypertension.23,24,27 Higher doses of thiazide 
Table 2. Association Between Thiazide Dose and Outcomes.
Drug group n n event (%)
Incidence rate per 
1000 person-years
Unadjusted HR 
(95% CI)
Adjusted HRa
(95% CI)
Adjusted 
P value
Primary outcome: Kidney stones
 Low dose 49°942 244 (0.49) 2.95 1.00 (reference) 1.00 (reference) —
 High dose 55°297 292 (0.53) 3.62 1.19
(1.01-1.41)
1.10
(0.93-1.31)
.26
Secondary outcome: Kidney stone surgery
 Low dose 49°942 154 (0.31) 1.86 1.00
(reference)
1.00
(reference)
—
 High dose 55°297 197 (0.36) 2.44 1.28
(1.03-1.58)
1.18
(0.96-1.46)
.12
Primary outcome: Kidney stonesb
 Low dose 49°942 378 (0.76) 2.97 1.00
(reference)
1.00
(reference)
—
 High dose 55°297 424 (0.77) 3.35 1.11
(0.96-1.27)
1.03
(0.89-1.18)
.70
Secondary outcome: Kidney stone surgeryb
 Low dose 49 942 253 (0.51) 1.98 1.00
(reference)
1.00
(reference)
—
 High dose 55 297 296 (0.54) 2.34 1.16
(0.98-1.37)
1.08
(0.91-1.28)
.36
Note. HR = hazard ratio; CI = confidence interval.
aModels were adjusted for the following factors: age (per 1 year), sex (male referent), location (urban referent), number of primary care provider 
visits in the prior year (per 1 visit), Charlson comorbidity score (per 1 unit increase), history of stroke, diabetes, hypertension, hypercalcemia, 
hyperparathyroidism, history of kidney stones, and inflammatory bowel disease.
bRepeated analysis without censoring the follow-up period for the start of a different antihypertensive.
Table 3. Sensitivity Analysis, Examining the Primary Outcome by Dose Switch.
Dose switches n n event (%)
Incidence rate per 
1000 person-years
Unadjusted HR 
(95% CI)
Adjusted HRa
(95% CI)
Adjusted 
P value
Low to low dose (referent) 41°776 199
(0.48)
2.87 1.00
(reference)
1.00
(reference)
—
Low to high dose 8166 45
(0.55)
3.30 1.18
(0.85-1.63)
1.19
(0.86-1.64)
.30
High to low dose 1693 14
(0.83)
6.39 2.12
(1.23-3.64)
2.19
(1.28-3.78)
.005
High to high dose 53°604 278
(0.52)
3.54 1.20
(1.00-1.44)
1.11
(0.92-1.33)
.27
Note. HR = hazard ratio; CI = confidence interval.
aModels were adjusted for the following factors: age (per 1 year), sex (male referent), location (urban referent), number of primary care provider 
visits in the prior year (per 1 visit), Charlson comorbidity score (per 1 unit increase), history of stroke, diabetes, hypertension, hypercalcemia, 
hyperparathyroidism, history of kidney stones, and inflammatory bowel disease.
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diuretics can lead to side effects such as hyperglycemia, hyper-
lipidemia, and glucose intolerance, which may increase the risk 
of cardiovascular disease.28 Thus, for the treatment of hyper-
tension, practitioners have used progressively lower doses. 
Fortunately, lower doses have a similar effect on reducing 
blood pressure and cardiovascular risk.29 One study suggests 
that practitioners have adopted these lower doses for the pre-
vention of kidney stones without any evidence that they remain 
effective for the prevention of recurrent kidney stone epi-
sodes.13 Consequently, there is currently a clinical trial examin-
ing this.30 We provide evidence that lower dose thiazide 
diuretics confer a similar protective effect to high-dose thiazide 
diuretics on the risk of having a kidney stone episode.
Despite employing a large cohort of patients prescribed a 
new thiazide diuretic, this work has limitations. Our outcome 
required the person to seek medical care for a kidney stone, and 
therefore we could not detect asymptomatic kidney stones or 
events for which an individual did not seek medical attention. 
This also prevented us from determining whether an event was 
due to a single stone or multiple and whether a recurrent event 
was due to a prior or new kidney stone. Although we adjusted 
for several confounders, including important comorbidities, we 
were unable to adjust for other potential confounders altering 
kidney stone formation risk, such as dietary factors. 
Furthermore, individuals were not randomly assigned a thia-
zide diuretic dose. Consequently, there is a risk of residual con-
founding. Our follow-up period was short; nonetheless, this 
time frame was sufficient to detect a difference in risk of stone 
presentation between different classes of antihypertensives.9 
Finally, our cohort only included individuals older than 65 
years of age, and whether or not our results are valid in a 
younger population needs to be confirmed.
Conclusions
We employed a large cohort of individuals receiving a new 
prescription for a thiazide diuretic to examine the relative 
risk of presenting with a kidney stone based on the dose (low 
vs high) of drug prescribed. We showed no difference in the 
likelihood of an event in those prescribed low- vs high-dose 
thiazide diuretics. These results are consistent with lower 
dose thiazide diuretics preventing kidney stones to the same 
degree as higher doses.
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Table 4. Subgroup Analysis.
Drug group n n event (%)
Adjusted RRa
(95% CI)
Interaction 
P value
Prior stones  
 Low dose (referent) 376 23 (6.12) 1.00
(reference)
.42
 High dose 449 40 (8.91) 1.26 (0.74-2.13)
No prior stones
 Low dose (referent) 49°566 221 (0.45%) 1.00
(reference)
 High dose 54°848 252 (0.46%) 1.08 (0.90-1.30)
Note. RR = relative risk; CI = confidence interval.
aModels were adjusted for the following factors: age (per 1 year), sex (male referent), location (urban referent), number of primary care provider 
visits in the prior year (per 1 visit), Charlson comorbidity score (per 1 unit increase), history of stroke, diabetes, hypertension, hypercalcemia, 
hyperparathyroidism, history of kidney stones, and inflammatory bowel disease.
Table 5. Recurrent Event Analysis.
Drug group n
n persons with 
an event (%)
Total number 
of events
Unadjusted HR 
(95% CI)
Adjusted HRa
(95% CI) Adjusted P value
Low dose 49°942 244 (0.49) 298 1.00 (reference) 1.00 (reference) —
High dose 55°297 292 (0.53) 356 1.22 (1.05-1.43) 1.11 (0.95-1.30) .19
Note. HR = hazard ratio; CI = confidence interval. Models were adjusted for the following factors: age (per 1 year), sex (male referent), location (urban 
referent), number of primary care provider visits in the prior year (per 1 visit), Charlson comorbidity score (per 1 unit increase), history of stroke, 
diabetes, hypertension, hypercalcemia, hyperparathyroidism, history of kidney stones, and inflammatory bowel disease.
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